Vaxcyte, Inc.
PCVX· Nasdaq
Released May 6, 2026, after the close
10-Q filed May 6, 2026, 36 days after period end · 0001649094-26-000017
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$320.62M | -$140.72M | -$95.02M | -$60.46M |
| EPS Diluted | -$2.30 | -$1.04 | -$0.85 | -$0.70 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR